Researchers have pioneered novel, gold nanoparticles, which bind and deform viruses rendering them inactive, thereby presenting potential in the development of a broad-spectrum antiviral.
Browsing: Basic > Drug Development
Want to find out what’s been happening this year? Editor, Martha Powell, highlights the best of 2017’s infectious diseases research in an A–Z.
In this World AIDS Day interview we speak to Richard Koup, who was recently an author on a study reporting a trispecific antibody able to target 99% of HIV strains.
Continuing our focus on antimicrobial resistance, Editor, Martha Powell, takes a closer look at the steps that can be taken to prevent the spread of drug resistance.
In this infographic we summarize the clinical candidates reported by the WHO – indicating which diseases they are active (or possibly active) against, whether they’re considered innovative and which Phase the trials are currently in.
In this piece, the authors give an overview of anti-virulence drugs, designed to selectively target key virulence factors of pathogenic bacteria, and one strategy for new antimicrobials.
Scientists have unveiled the molecular architecture of two key proteins required for bacillus cell wall elongation. Inhibiting their interaction could provide a new mode of action for antibiotics against highly resistant bacteria.
New drugs with antifungal action need to be developed. Here, the authors investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp.
This research reports the synthesis of capped gold nanoparticles by reducing HAuCl4 with flower and leaf extracts of Ocimum tenuiflorum, leaves of Azadirachta indica and Mentha spicata and peel of Citrus sinensis plants and assessed their activity on Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae.